Mustang Bio, Inc. (MBIO) 10-Year Financial Performance & Capital Metrics

MBIO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Show more

Revenue $0
EBITDA -$15M +68.2%
Net Income -$16M +69.5%
EPS (Diluted) -2.57 +57.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 28.8% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM90.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM51.81%

ROCE

10Y Avg-64.85%

5Y Avg-84.34%

3Y Avg-103.39%

Latest-

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	2K	630K	1.37M	1.78M	2.31M	3.03M	2.23M	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-2K	-630K	-1.37M	-1.78M	-2.31M	-3.03M	-2.23M	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-314%	-1.17%	-0.3%	-0.29%	-0.31%	0.27%	1%
Operating Expenses+	4.3M	11.36M	31.79M	31.22M	45.88M	55.02M	64.42M	73.13M	48.5M	16.25M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	254K	2.82M	11.41M	6.76M	9.57M	9.51M	11.02M	12.21M	9.32M	4.13M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	4.04M	8.55M	20.38M	24.46M	36.31M	45.62M	53.54M	63.95M	39.18M	8.42M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	3.36M	0	-108K	-139K	-3.03M	0	3.69M
Operating Income+	-4.3M	11.36M	-31.79M	-31.22M	-45.88M	-56.81M	-66.72M	-76.16M	-50.73M	-16.25M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	3.64%	-3.8%	0.02%	-0.47%	-0.24%	-0.17%	-0.14%	0.33%	0.68%
EBITDA+	-4.3M	-11.35M	-31.78M	-30.59M	-44.52M	-55.02M	-64.42M	-73.13M	-48.5M	-15.42M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.64%	-1.8%	0.04%	-0.46%	-0.24%	-0.17%	-0.14%	0.34%	0.68%
D&A (Non-Cash Add-back)	0	-22.71M	2K	630K	1.37M	1.78M	2.31M	3.03M	2.23M	823K
EBIT	-4.3M	-11.51M	-31.28M	-30.65M	-44.62M	-56.1M	-66.36M	-74.17M	-50.29M	-15.75M
Net Interest Income+	0	-1.13M	497K	561K	-504K	-3.21M	353K	-2.67M	-464K	189K
Interest Income	0	16K	505K	569K	1.26M	708K	368K	689K	850K	184K
Interest Expense	168K	1.15M	8K	8K	1.77M	3.92M	15K	3.36M	1.31M	-5K
Other Income/Expense	-168K	-24.02M	497K	561K	-504K	-3.21M	353K	-1.37M	-876K	493K
Pretax Income+	-4.47M	-12.65M	-31.29M	-30.66M	-46.39M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.04%	1%	1%	1%	1%	1%
Net Income+	-4.47M	-12.65M	-31.29M	-30.66M	-48.16M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-1.83%	-1.47%	0.02%	-0.57%	-0.25%	-0.11%	-0.17%	0.33%	0.69%
Net Income (Continuing)	-4.47M	-12.65M	-31.29M	-30.66M	-46.39M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-6.70	-7.24	-18.58	-17.07	-20.03	-17.10	-11.40	-11.25	-6.00	-2.57
EPS Growth %	-	-0.08%	-1.57%	0.08%	-0.17%	0.15%	0.33%	0.01%	0.47%	0.57%
EPS (Basic)	-6.70	-7.24	-18.58	-17.07	-20.03	-17.10	-11.40	-11.25	-6.00	-2.57
Diluted Shares Outstanding	666.21K	1.75M	1.68M	1.8M	2.4M	3.51M	5.86M	6.9M	8.6M	6.13M
Basic Shares Outstanding	666.21K	1.75M	1.68M	1.8M	2.4M	3.51M	5.86M	6.9M	8.6M	6.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	0	27.5M	61.36M	35.13M	63.06M	99.53M	111.71M	78.85M	11.35M	8.61M
Cash & Short-Term Investments	0	27.5M	60.98M	34.07M	61.41M	97.8M	109.62M	75.66M	6.23M	6.84M
Cash Only	0	27.5M	34.98M	16.47M	61.41M	97.8M	109.62M	75.66M	6.23M	6.84M
Short-Term Investments	0	0	26M	17.6M	0	0	0	0	0	0
Accounts Receivable	0	0	106K	37K	19K	15K	50K	0	3.88M	402K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	299K	1.23M	1.36M
Total Non-Current Assets+	0	0	2.13M	7.63M	10.38M	10.37M	13.46M	13.57M	6.4M	702K
Property, Plant & Equipment	0	0	1.38M	6.86M	9.13M	9.12M	12.1M	12.31M	4.81M	452K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	500K	500K	1M	0	0	0	0	0
Other Non-Current Assets	0	0	251K	271K	250K	1.25M	1.36M	1.26M	1.58M	250K
Total Assets+	0	27.5M	63.49M	42.75M	73.44M	109.9M	125.17M	92.42M	17.74M	9.31M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-	1.31%	-0.33%	0.72%	0.5%	0.14%	-0.26%	-0.81%	-0.48%
Total Current Liabilities+	4.13M	3.22M	3.61M	5.62M	7.77M	9.52M	10.81M	15.11M	15.37M	12.61M
Accounts Payable	15K	683K	3.47M	1.39M	1.88M	3.52M	3.51M	6.83M	6.32M	7.46M
Days Payables Outstanding	-	-	634K	803	500.81	719.37	555.89	822.85	1.04K	-
Short-Term Debt	3.57M	320K	0	0	1.25M	0	0	0	0	0
Deferred Revenue (Current)	0	538K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	1.36M	137K	1.09M	2.03M	848K	2.6M	648K	2.84M	93K
Current Ratio	-	8.53x	16.99x	6.25x	8.12x	10.46x	10.33x	5.22x	0.74x	0.68x
Quick Ratio	-	8.53x	16.99x	6.25x	8.12x	10.46x	10.33x	5.22x	0.74x	0.68x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.59M	1M	50K	741K	14.02M	1.95M	1.96M	31.04M	2.25M	572K
Long-Term Debt	0	0	0	0	12.18M	0	0	27.44M	0	0
Capital Lease Obligations	0	0	0	0	1.84M	1.95M	1.69M	3.33M	1.98M	422K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	50K	741K	0	0	0	270K	0	0
Total Liabilities	4.13M	3.22M	3.66M	6.36M	21.79M	11.46M	12.77M	46.15M	17.62M	13.18M
Total Debt+	3.57M	320K	0	0	15.53M	2.23M	2.03M	31.38M	2.5M	878K
Net Debt	3.57M	-27.18M	-34.98M	-16.47M	-45.88M	-95.58M	-107.58M	-44.27M	-3.74M	-5.96M
Debt / Equity	-	0.01x	-	-	0.30x	0.02x	0.02x	0.68x	20.31x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-25.58x	9.90x	-3973.13x	-3902.88x	-25.97x	-14.50x	-4448.20x	-22.67x	-38.60x	-
Total Equity+	-4.13M	24.28M	59.83M	36.4M	51.65M	98.44M	112.4M	46.27M	123K	-3.87M
Equity Growth %	-	6.88%	1.46%	-0.39%	0.42%	0.91%	0.14%	-0.59%	-1%	-32.49%
Book Value per Share	-6.20	13.88	35.54	20.26	21.48	28.08	19.18	6.71	0.01	-0.63
Total Shareholders' Equity	-4.13M	24.28M	59.83M	36.4M	51.65M	98.44M	112.4M	46.27M	123K	-3.87M
Common Stock	1K	2K	3K	3K	4K	7K	9K	11K	1K	5K
Retained Earnings	-4.47M	-17.12M	-48.41M	-79.07M	-125.46M	-185.47M	-251.84M	-329.37M	-380.97M	-396.72M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	4.4M	9.56M	2.08M	4.92M	0	0	1.11M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.57M	-4.13M	-12.95M	-19.24M	-33.58M	-37.32M	-53.67M	-65.07M	-49.48M	-11.41M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-1.63%	-2.14%	-0.49%	-0.75%	-0.11%	-0.44%	-0.21%	0.24%	0.77%
Net Income	-4.47M	-12.65M	-31.29M	-30.66M	-46.39M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Depreciation & Amortization	0	0	2K	630K	1.37M	1.78M	2.31M	3.03M	2.23M	823K
Stock-Based Compensation	0	0	2.01M	4.96M	2.66M	2.99M	3.31M	2.28M	568K	-450K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	2.34M	7.86M	15.73M	3.36M	8.64M	14.83M	7.73M	3.12M	2.31M	4.6M
Working Capital Changes	558K	663K	597K	2.47M	132K	3.09M	-637K	4.03M	-2.98M	-628K
Change in Receivables	0	0	-106K	-35K	-19K	4K	-35K	14K	-3.58M	494K
Change in Inventory	0	0	0	0	19K	-4K	35K	-14K	0	0
Change in Payables	0	668K	1.33M	2.47M	296K	3.15M	-175K	5.3M	192K	-2.97M
Cash from Investing+	-2M	0	-29.05M	557K	13.91M	-4.41M	-5.37M	-2.95M	5.89M	0
Capital Expenditures	0	0	-2.8M	-7.95M	-3.69M	-4.41M	-5.37M	-3.08M	-64K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2M	0	2.12M	-1.07M	0	0	0	0	5.95M	0
Cash from Financing+	3.57M	31.63M	49.98M	181K	65.12M	78.12M	70.85M	34.06M	-26.08M	11.27M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-611K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.57M	0	0	181K	-4.02M	-3.16M	-1.07M	-2.57M	-267K	2.73M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.57M	-4.13M	-15.75M	-27.19M	-37.28M	-41.73M	-59.03M	-68.14M	-49.59M	-11.41M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.63%	-2.81%	-0.73%	-0.37%	-0.12%	-0.41%	-0.15%	0.27%	0.77%
FCF per Share	-2.36	-2.36	-9.35	-15.13	-15.51	-11.90	-10.08	-9.88	-5.76	-1.86
FCF Conversion (FCF/Net Income)	0.35x	0.33x	0.41x	0.63x	0.70x	0.62x	0.81x	0.84x	0.96x	0.72x
Interest Paid	0	0	0	0	0	0	0	0	1.34M	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-125.62%	-74.4%	-63.73%	-109.39%	-79.97%	-62.96%	-97.72%	-222.44%	-
Return on Invested Capital (ROIC)	-	-	-217.17%	-104.58%	-267.86%	-987.7%	-1304.2%	-1676.53%	-	-
Debt / Equity	-	0.01x	-	-	0.30x	0.02x	0.02x	0.68x	20.31x	-
Interest Coverage	-25.58x	9.90x	-3973.13x	-3902.88x	-25.97x	-14.50x	-4448.20x	-22.67x	-38.60x	-
FCF Conversion	0.35x	0.33x	0.41x	0.63x	0.70x	0.62x	0.81x	0.84x	0.96x	0.72x

Frequently Asked Questions

Growth & Financials

Mustang Bio, Inc. (MBIO) grew revenue by 0.0% over the past year. Growth has been modest.

Mustang Bio, Inc. (MBIO) reported a net loss of $2.3M for fiscal year 2024.

Dividend & Returns

Yes, Mustang Bio, Inc. (MBIO) pays a dividend with a yield of 9.50%. This makes it attractive for income-focused investors.

Mustang Bio, Inc. (MBIO) had negative free cash flow of $5.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Mustang Bio, Inc. (MBIO) 10-Year Financial Performance & Capital Metrics

MBIO • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $0
EBITDA -$15M +68.2%
Net Income -$16M +69.5%
EPS (Diluted) -2.57 +57.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Share count reduced 28.8% through buybacks

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Weak momentum: RS Rating 15 (bottom 15%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM90.03%

EPS CAGR

10Y-

5Y-

3Y-

TTM51.81%

ROCE

10Y Avg-64.85%

5Y Avg-84.34%

3Y Avg-103.39%

Latest-

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	2K	630K	1.37M	1.78M	2.31M	3.03M	2.23M	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	-2K	-630K	-1.37M	-1.78M	-2.31M	-3.03M	-2.23M	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-314%	-1.17%	-0.3%	-0.29%	-0.31%	0.27%	1%
Operating Expenses+	4.3M	11.36M	31.79M	31.22M	45.88M	55.02M	64.42M	73.13M	48.5M	16.25M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	254K	2.82M	11.41M	6.76M	9.57M	9.51M	11.02M	12.21M	9.32M	4.13M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	4.04M	8.55M	20.38M	24.46M	36.31M	45.62M	53.54M	63.95M	39.18M	8.42M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	3.36M	0	-108K	-139K	-3.03M	0	3.69M
Operating Income+	-4.3M	11.36M	-31.79M	-31.22M	-45.88M	-56.81M	-66.72M	-76.16M	-50.73M	-16.25M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	3.64%	-3.8%	0.02%	-0.47%	-0.24%	-0.17%	-0.14%	0.33%	0.68%
EBITDA+	-4.3M	-11.35M	-31.78M	-30.59M	-44.52M	-55.02M	-64.42M	-73.13M	-48.5M	-15.42M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-1.64%	-1.8%	0.04%	-0.46%	-0.24%	-0.17%	-0.14%	0.34%	0.68%
D&A (Non-Cash Add-back)	0	-22.71M	2K	630K	1.37M	1.78M	2.31M	3.03M	2.23M	823K
EBIT	-4.3M	-11.51M	-31.28M	-30.65M	-44.62M	-56.1M	-66.36M	-74.17M	-50.29M	-15.75M
Net Interest Income+	0	-1.13M	497K	561K	-504K	-3.21M	353K	-2.67M	-464K	189K
Interest Income	0	16K	505K	569K	1.26M	708K	368K	689K	850K	184K
Interest Expense	168K	1.15M	8K	8K	1.77M	3.92M	15K	3.36M	1.31M	-5K
Other Income/Expense	-168K	-24.02M	497K	561K	-504K	-3.21M	353K	-1.37M	-876K	493K
Pretax Income+	-4.47M	-12.65M	-31.29M	-30.66M	-46.39M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1.04%	1%	1%	1%	1%	1%
Net Income+	-4.47M	-12.65M	-31.29M	-30.66M	-48.16M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-1.83%	-1.47%	0.02%	-0.57%	-0.25%	-0.11%	-0.17%	0.33%	0.69%
Net Income (Continuing)	-4.47M	-12.65M	-31.29M	-30.66M	-46.39M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-6.70	-7.24	-18.58	-17.07	-20.03	-17.10	-11.40	-11.25	-6.00	-2.57
EPS Growth %	-	-0.08%	-1.57%	0.08%	-0.17%	0.15%	0.33%	0.01%	0.47%	0.57%
EPS (Basic)	-6.70	-7.24	-18.58	-17.07	-20.03	-17.10	-11.40	-11.25	-6.00	-2.57
Diluted Shares Outstanding	666.21K	1.75M	1.68M	1.8M	2.4M	3.51M	5.86M	6.9M	8.6M	6.13M
Basic Shares Outstanding	666.21K	1.75M	1.68M	1.8M	2.4M	3.51M	5.86M	6.9M	8.6M	6.13M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	0	27.5M	61.36M	35.13M	63.06M	99.53M	111.71M	78.85M	11.35M	8.61M
Cash & Short-Term Investments	0	27.5M	60.98M	34.07M	61.41M	97.8M	109.62M	75.66M	6.23M	6.84M
Cash Only	0	27.5M	34.98M	16.47M	61.41M	97.8M	109.62M	75.66M	6.23M	6.84M
Short-Term Investments	0	0	26M	17.6M	0	0	0	0	0	0
Accounts Receivable	0	0	106K	37K	19K	15K	50K	0	3.88M	402K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	299K	1.23M	1.36M
Total Non-Current Assets+	0	0	2.13M	7.63M	10.38M	10.37M	13.46M	13.57M	6.4M	702K
Property, Plant & Equipment	0	0	1.38M	6.86M	9.13M	9.12M	12.1M	12.31M	4.81M	452K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	500K	500K	1M	0	0	0	0	0
Other Non-Current Assets	0	0	251K	271K	250K	1.25M	1.36M	1.26M	1.58M	250K
Total Assets+	0	27.5M	63.49M	42.75M	73.44M	109.9M	125.17M	92.42M	17.74M	9.31M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	-	1.31%	-0.33%	0.72%	0.5%	0.14%	-0.26%	-0.81%	-0.48%
Total Current Liabilities+	4.13M	3.22M	3.61M	5.62M	7.77M	9.52M	10.81M	15.11M	15.37M	12.61M
Accounts Payable	15K	683K	3.47M	1.39M	1.88M	3.52M	3.51M	6.83M	6.32M	7.46M
Days Payables Outstanding	-	-	634K	803	500.81	719.37	555.89	822.85	1.04K	-
Short-Term Debt	3.57M	320K	0	0	1.25M	0	0	0	0	0
Deferred Revenue (Current)	0	538K	0	0	0	0	0	0	0	0
Other Current Liabilities	0	1.36M	137K	1.09M	2.03M	848K	2.6M	648K	2.84M	93K
Current Ratio	-	8.53x	16.99x	6.25x	8.12x	10.46x	10.33x	5.22x	0.74x	0.68x
Quick Ratio	-	8.53x	16.99x	6.25x	8.12x	10.46x	10.33x	5.22x	0.74x	0.68x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	3.59M	1M	50K	741K	14.02M	1.95M	1.96M	31.04M	2.25M	572K
Long-Term Debt	0	0	0	0	12.18M	0	0	27.44M	0	0
Capital Lease Obligations	0	0	0	0	1.84M	1.95M	1.69M	3.33M	1.98M	422K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	50K	741K	0	0	0	270K	0	0
Total Liabilities	4.13M	3.22M	3.66M	6.36M	21.79M	11.46M	12.77M	46.15M	17.62M	13.18M
Total Debt+	3.57M	320K	0	0	15.53M	2.23M	2.03M	31.38M	2.5M	878K
Net Debt	3.57M	-27.18M	-34.98M	-16.47M	-45.88M	-95.58M	-107.58M	-44.27M	-3.74M	-5.96M
Debt / Equity	-	0.01x	-	-	0.30x	0.02x	0.02x	0.68x	20.31x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-25.58x	9.90x	-3973.13x	-3902.88x	-25.97x	-14.50x	-4448.20x	-22.67x	-38.60x	-
Total Equity+	-4.13M	24.28M	59.83M	36.4M	51.65M	98.44M	112.4M	46.27M	123K	-3.87M
Equity Growth %	-	6.88%	1.46%	-0.39%	0.42%	0.91%	0.14%	-0.59%	-1%	-32.49%
Book Value per Share	-6.20	13.88	35.54	20.26	21.48	28.08	19.18	6.71	0.01	-0.63
Total Shareholders' Equity	-4.13M	24.28M	59.83M	36.4M	51.65M	98.44M	112.4M	46.27M	123K	-3.87M
Common Stock	1K	2K	3K	3K	4K	7K	9K	11K	1K	5K
Retained Earnings	-4.47M	-17.12M	-48.41M	-79.07M	-125.46M	-185.47M	-251.84M	-329.37M	-380.97M	-396.72M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	4.4M	9.56M	2.08M	4.92M	0	0	1.11M	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.57M	-4.13M	-12.95M	-19.24M	-33.58M	-37.32M	-53.67M	-65.07M	-49.48M	-11.41M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-1.63%	-2.14%	-0.49%	-0.75%	-0.11%	-0.44%	-0.21%	0.24%	0.77%
Net Income	-4.47M	-12.65M	-31.29M	-30.66M	-46.39M	-60.02M	-66.37M	-77.53M	-51.6M	-15.75M
Depreciation & Amortization	0	0	2K	630K	1.37M	1.78M	2.31M	3.03M	2.23M	823K
Stock-Based Compensation	0	0	2.01M	4.96M	2.66M	2.99M	3.31M	2.28M	568K	-450K
Deferred Taxes	0	0	0	0	0	0	0	0	0	0
Other Non-Cash Items	2.34M	7.86M	15.73M	3.36M	8.64M	14.83M	7.73M	3.12M	2.31M	4.6M
Working Capital Changes	558K	663K	597K	2.47M	132K	3.09M	-637K	4.03M	-2.98M	-628K
Change in Receivables	0	0	-106K	-35K	-19K	4K	-35K	14K	-3.58M	494K
Change in Inventory	0	0	0	0	19K	-4K	35K	-14K	0	0
Change in Payables	0	668K	1.33M	2.47M	296K	3.15M	-175K	5.3M	192K	-2.97M
Cash from Investing+	-2M	0	-29.05M	557K	13.91M	-4.41M	-5.37M	-2.95M	5.89M	0
Capital Expenditures	0	0	-2.8M	-7.95M	-3.69M	-4.41M	-5.37M	-3.08M	-64K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-2M	0	2.12M	-1.07M	0	0	0	0	5.95M	0
Cash from Financing+	3.57M	31.63M	49.98M	181K	65.12M	78.12M	70.85M	34.06M	-26.08M	11.27M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-611K
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.57M	0	0	181K	-4.02M	-3.16M	-1.07M	-2.57M	-267K	2.73M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.57M	-4.13M	-15.75M	-27.19M	-37.28M	-41.73M	-59.03M	-68.14M	-49.59M	-11.41M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-1.63%	-2.81%	-0.73%	-0.37%	-0.12%	-0.41%	-0.15%	0.27%	0.77%
FCF per Share	-2.36	-2.36	-9.35	-15.13	-15.51	-11.90	-10.08	-9.88	-5.76	-1.86
FCF Conversion (FCF/Net Income)	0.35x	0.33x	0.41x	0.63x	0.70x	0.62x	0.81x	0.84x	0.96x	0.72x
Interest Paid	0	0	0	0	0	0	0	0	1.34M	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-125.62%	-74.4%	-63.73%	-109.39%	-79.97%	-62.96%	-97.72%	-222.44%	-
Return on Invested Capital (ROIC)	-	-	-217.17%	-104.58%	-267.86%	-987.7%	-1304.2%	-1676.53%	-	-
Debt / Equity	-	0.01x	-	-	0.30x	0.02x	0.02x	0.68x	20.31x	-
Interest Coverage	-25.58x	9.90x	-3973.13x	-3902.88x	-25.97x	-14.50x	-4448.20x	-22.67x	-38.60x	-
FCF Conversion	0.35x	0.33x	0.41x	0.63x	0.70x	0.62x	0.81x	0.84x	0.96x	0.72x

Frequently Asked Questions

Growth & Financials

Mustang Bio, Inc. (MBIO) grew revenue by 0.0% over the past year. Growth has been modest.

Mustang Bio, Inc. (MBIO) reported a net loss of $2.3M for fiscal year 2024.

Dividend & Returns

Yes, Mustang Bio, Inc. (MBIO) pays a dividend with a yield of 9.50%. This makes it attractive for income-focused investors.

Mustang Bio, Inc. (MBIO) had negative free cash flow of $5.5M in fiscal year 2024, likely due to heavy capital investments.